| Protocol Number | Protocol ID | Protocol Title |
| HPTN 035 | 10065 | Phase II/IIb Safety and Effectiveness Study of the Vaginal Microbicides BufferGel and 0.5% PRO2000/5 Gel (P) for the Prevention of HIV Infection in Women |
| HPTN 059 | 10145 | Phase II Expanded Safety and Acceptability Study of the Vaginal Microbicide 1% Tenofovir Gel |
| HVTN 095/MTN-022 | 11852 | Phase 1 Safety and Immunogenicity of DNA/NYVAC Prime Boost Vaccination With/Without Emtricitabine/Tenofovir |
| MTN-003D | 11893 | An Exploratory Study of Potential Sources of Efficacy Dilution in the VOICE Trial |
| MTN-014 | 11885 | A Phase 1 Crossover Trial Evaluating the Pharmacokinetics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments In Women |
| MTN-017 | 11857 | A Phase 2 Randomized Sequence Open Label Expanded Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel. |
| MTN-018 | 11818 | Post-Trial Follow-up Safety Study to MTN-003 |
| MTN-018B | 11846 | Committed to Having Options for Interventions to Control the Epidemic: A Follow-up Study to MTN-003 - Breastfeeding Sub-study |
| MTN-018C | 11847 | Committed to Having Options for Interventions to Control the Epidemic: A Follow-up Study to MTN-003 - Pregnancy Sub-study |
| MTN-024/IPM 031 | 11915 | Phase 2a Safety and Acceptability Study of a Vaginal Matrix Ring Containing Dapivirine in a Post-Menopausal Female Population |
| MTN-001 | 10617 | Phase 2 Adherence and Pharmacokinetics Study of Oral and Vaginal Preparations of Tenofovir |
| MTN-002 | 10600 | Phase I Study of the Maternal Single-Dose Pharmacokinetics and Placental Transfer of Tenofovir 1% Vaginal Gel among Healthy Term Gravidas |
| MTN-003-P01 | 11835 | The Wisebag Observational Pilot Study: Feasibility, Acceptability and Performance of an Electronic Event-based Monitoring System (Wisebag) |
| MTN-004 | 10492 | Phase 1 Study of the Safety and Acceptability of 3% w/w SPL7013 Gel (VivaGel®) Applied Vaginally in Sexually Active Young Women |
| MTN-007 | 10736 | A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel |
| MTN-009 | 10791 | Prevalence of HIV-1 Drug Resistance within a Female Screening Population for HIV Prevention Trials |
| MTN-012/IPM 010 | 11771 | Male Tolerance Study of Dapivirine Gel Following Multiple Topical Penile Exposures |
| RMP-02/MTN-006 | 10769 | Phase 1 rectal microbicide safety and acceptability trial of topically applied tenofovir compared with oral tablet |
| MTN-003 | 10622 | Phase 2B Safety and Effectiveness Study of Tenofovir 1% Gel, Tenofovir Disoproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil Fumarate Tablet for the Prevention of HIV Infection in Women |
| MTN-003C | 10746 | Household and Community Level Factors Associated with Study Product Adherence in VOICE: A Substudy of MTN-003 |
| MTN-005 | 10635 | Expanded Safety and Acceptability Study of a Non-medicated Intravaginal Ring |
| MTN-013/IPM 026 | 11772 | Phase 1 Safety and Pharmacokinetics of Dapivirine/Maraviroc Intravaginal Ring |
| MTN-003B | 10709 | Bone Mineral Density Substudy |
| MTN-003C-01 | 11860 | PREMIS: Preventive Misconception in HIV Prevention Trials |
| MTN-010 | 11682 | Phase 2 Expanded Safety Study of UC781 0.25% Gel Used Daily Among Sexually Active Women |
| MTN-019 | 11839 | Phase 2 Expanded Safety Study of Tenofovir Gel in Pregnancy |
| MTN-021 | 11843 | Phase 1 Safety and Acceptability Study of 1% Tenofovir Gel in Adolescent Females |
| MTN-008 | 10805 | Expanded Safety of Tenofovir 1% Gel in Pregnancy and Lactation |
| MTN-011 | 11825 | Phase 1 Evaluation of Coitus on the Pharmacokinetics and Pharmacodynamics of Tenofovir 1% Gel Following Pericoital or Daily Gel Dosing |
| MTN-015 | 10529 | An Observational Cohort Study of Women following HIV-1 Seroconversion in Microbicide Trials |
| MTN-016 | 10737 | HIV Prevention Agent Pregnancy Exposure Registry |
| MTN-020 | 11840 | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 3 Safety and Effectiveness Trial of a Vaginal Matrix Ring Containing Dapivirine for the Prevention of HIV-1 Infection in Women |
